Global Tinea Pedis Treatment Market to Grow at a CAGR of 3% by 2021 - Key Vendors Are GSK, Exeltis USA, Valeant & Viamet Pharmaceuticals - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Tinea Pedis Treatment Market 2017-2021" report to their offering.

The global tinea pedis treatment market to grow at a CAGR of 3.03% during the period 2017-2021.

This report, Global Tinea Pedis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion operating in this market.

According to the report, one of the major drivers for this market is high unmet needs. The global tinea pedis treatment market faces significant unmet needs due to low treatment efficacy and prolonged treatment duration. Certain drugs show their efficacy only in the treatment of mild cases of infection. Also, the infection continues to recur as the treatment does not completely cure it. Multiple cycles of unsuccessful treatments increase patient discomfort. This creates a large gap between the demand for and supply of these therapeutics. Thus, the market provides a growth opportunity for vendors with the increasing demand for effective pharmacological therapeutics for fungal infections.

Key vendors:

  • GSK
  • Exeltis USA
  • Valeant
  • Viamet Pharmaceuticals

Other prominent vendors:

  • Allergan
  • Almirall
  • Amgen
  • Aqua Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Celgene
  • Dermira
  • Elorac
  • Others

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Pipeline landscape

Part 06: Market landscape

Part 07: Market segmentation by ROA

Part 08: Market segmentation by disease type

Part 09: Geographical segmentation

Part 10: Decision framework

Part 11: Drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/4mtzg7/global_tinea

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Dermatological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Dermatological Drugs